Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase II Trial of ADX-914 for Atopic Dermatitis

Q32 Bio and Horizon Therapeutics plc announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase II multi-center proof-of-concept study in adult subjects to evaluate the safety and efficacy of ADX-914 in persistent, moderate-to-severe atopic dermati.